Equities

PAVmed Inc

PAVM:NAQ

PAVmed Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.61
  • Today's Change-0.04 / -2.42%
  • Shares traded50.83k
  • 1 Year change-60.01%
  • Beta0.6563
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.

  • Revenue in USD (TTM)3.83m
  • Net income in USD-67.35m
  • Incorporated2014
  • Employees107.00
  • Location
    PAVmed Inc360 Madison Avenue, 25Th FloorNEW YORK 10017United StatesUSA
  • Phone+1 (212) 949-4319
  • Fax+1 (302) 655-5049
  • Websitehttps://pavmed.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Applied DNA Sciences Inc3.40m-7.52m12.46m53.00--1.01--3.67-11.86-11.862.181.200.20926.835.6864,114.15-45.51-88.57-55.20-121.9125.0444.35-217.48-113.263.76--0.00---26.4327.92-18.73--33.80--
QT Imaging Holdings Inc0.00-4.02m12.86m----0.5917-----0.3999-0.39990.001.010.00-------12.32---16.60--------------0.3042-------45.07------
Vapotherm Inc70.92m-54.42m13.55m182.00------0.1911-8.50-8.5011.08-13.030.89771.568.11389,664.80-68.88-49.73---62.5446.7443.56-76.74-78.990.0934-1.063.19--2.8010.1448.62---10.38--
REMSleep Holdings Inc144.88k-1.81m14.41m6.00--25.06--99.46-0.0012-0.00120.00010.00040.081.694.75---99.82-152.40-122.32-317.98-491.08---1,246.94-2,317.521.47-43.580.1207---36.48--12.13--28.26--
Trinity Biotech plc (ADR)58.65m-22.29m14.55m380.00------0.2482-2.74-2.747.23-19.240.70521.693.74154,347.40-26.80-20.30-35.44-29.5434.2839.92-38.01-29.860.8936-2.161.46---9.10-10.1515.41---31.08--
Autonomix Medical Inc-100.00bn-100.00bn15.01m5.00--2.37----------0.2749----------------------------0.1647-------674.99------
LiveCare Inc0.00-2.34m15.26m----6.47-----0.1411-0.14110.000.04630.00-------424.83---550.62-------------8.180.1888-------344.86------
Cutera Inc169.19m-148.97m15.50m430.00------0.0916-7.46-7.468.46-10.730.45722.083.86393,460.50-40.25-22.00-51.64-30.728.1847.63-88.05-27.242.17-31.342.05---15.865.47-97.76--85.87--
Innovative Eyewear Inc1.53m-7.86m15.53m11.00--2.06--10.15-11.01-11.012.054.810.17791.9715.91139,070.90-91.45---96.06---2.46---514.10--12.85--0.00--74.67---17.28------
BioRegenx Inc634.81k-727.95k17.12m10.00--1.01--26.97-0.001-0.0010.00160.01780.0617----63,481.00-7.07---8.46--74.90---114.67--0.1547-8.800.0977---47.25---629.37------
PAVmed Inc3.83m-67.35m17.17m107.00------4.48-8.17-8.170.4595-7.740.0823--29.4535,785.05-155.93-154.56---1,152.82-77.59---1,895.64-8,764.890.5529-8.161.74--550.40--25.76--55.51--
Beyond Air Inc1.78m-58.35m17.78m107.00--1.09--9.97-1.65-1.650.04850.35140.02981.706.8716,663.55-104.22-78.25-137.64-99.91-78.30---3,493.78-6,152.992.42-38.110.4666-----31.57-7.93--152.05--
Spectral AI Inc22.53m-20.24m19.01m78.00------0.8439-1.48-1.481.55-0.24221.68--11.54288,859.00-150.54---954.46--45.12---89.85--0.7066--2.14---28.82---616.14------
Neuraxis Inc2.27m-15.26m20.05m19.00------8.84-3.09-3.090.4039-0.76861.096.6311.80119,318.90-731.17------87.29---672.94--0.2724-19.01-----8.37---163.78------
SeaStar Medical Holding Corp0.00-33.23m20.79m12.00---------21.41-21.410.00-2.140.00----0.00-1,145.80-----------------9.51---------115.19------
Data as of Sep 20 2024. Currency figures normalised to PAVmed Inc's reporting currency: US Dollar USD

Institutional shareholders

13.53%Per cent of shares held by top holders
HolderShares% Held
First Manhattan Co LLCas of 30 Jun 2024500.00k4.81%
Ayrton Capital LLCas of 31 Dec 2023382.98k3.68%
The Vanguard Group, Inc.as of 30 Jun 2024293.59k2.82%
BlackRock Fund Advisorsas of 30 Jun 202474.91k0.72%
Geode Capital Management LLCas of 30 Jun 202473.63k0.71%
Two Sigma Securities LLCas of 30 Jun 202425.23k0.24%
SSgA Funds Management, Inc.as of 30 Jun 202420.85k0.20%
Virtu Americas LLCas of 30 Jun 202415.10k0.15%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 202411.71k0.11%
XML Financial LLCas of 30 Jun 202410.07k0.10%
More ▼
Data from 03 Apr 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.